nach oben

NanoEthics

Erschienen in:

05.08.2017 | Original Paper

Nanotechnology and Risk Governance in the European Union: the Constitution of Safety in Highly Promoted and Contested Innovation Areas

verfasst von: Hannot Rodríguez

Erschienen in: NanoEthics | Ausgabe 1/2018

Einloggen

Aktivieren Sie unsere intelligente Suche, um passende Fachinhalte oder Patente zu finden.

search-config

KI-gestützte Suche

Aus

Abstract

The European Union (EU) is strategically committed to the development of nanotechnology and its industrial exploitation. However, nanotechnology also has the potential to disrupt human health and the environment. The EU claims to be committed to the safe and responsible development of nanotechnology. In this sense, the EU has become the first governing body in the world to develop nanospecific regulations, largely due to legislative action taken by the European Parliament, which has compensated for the European Commission’s reluctance to develop special regulations for nanomaterials. Nevertheless, divergences aside, political bodies in the EU assume that nanotechnology development is controllable and take for granted that both the massive industrial use of nanomaterials and a high level of environmental and health protection are compatible. However, experiences such as the European controversy over agri-food biotechnology, which somewhat delegitimized the regulatory authority of the EU over technological safety and acceptability, arguably show that controllability assumptions are contestable on the grounds of alternative socio-economic and cultural preferences and values. Recently developed inclusive governance models on safety and innovation, such as “Responsible Research and Innovation” (RRI), widely claim that a diversity of considerations and issues are integrated into R&D processes. Even so, the possibility of more radically alternative constitutions of socio-technical safety seems to be seriously limited by the current ideology of innovation and economic imperatives of the global, knowledge-based, capitalist economy.

Vorheriger Artikel Discussions of Risk and New Approaches to Responsible Research and Innovation

Nächster Artikel Governing with Ignorance: Understanding the Australian Food Regulator’s Response to Nano Food

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

über 102.000 Bücher
über 537 Zeitschriften

aus folgenden Fachgebieten:

Automobil + Motoren
Bauwesen + Immobilien
Business IT + Informatik
Elektrotechnik + Elektronik
Energie + Nachhaltigkeit
Finance + Banking
Management + Führung
Marketing + Vertrieb
Maschinenbau + Werkstoffe
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

Springer Professional "Wirtschaft"

Online-Abonnement

Mit Springer Professional "Wirtschaft" erhalten Sie Zugriff auf:

über 67.000 Bücher
über 340 Zeitschriften

aus folgenden Fachgebieten:

Bauwesen + Immobilien
Business IT + Informatik
Finance + Banking
Management + Führung
Marketing + Vertrieb
Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Jetzt informieren

For instance, estimates show that 160,000 nanorelated jobs already existed globally in 2008, representing a 25% increase from 2000, and that every euro invested in research areas such as nanotechnology results in a tenfold return, largely affecting small- and medium-sized enterprises (SMEs). SMEs are expected to account for most nanorelated jobs. In Germany, for example, 80% of nanotechnology firms are small- or medium-sized ([55], pp. 3–4).

“Responsible innovation” for the EC not only refers to environmental, health and safety (EHS) risks but also to ethical and societal consequences.

For instance, global public and private investment in nanotechnology R&D had risen to more than US$18 billion annually during the last decade ([112], p. 174). The world market for nanomaterials has been evaluated at 11 million tonnes (having a market value of €20 billion), direct employment in the nanotechnology sector stands at 300,000–400,000 jobs across the EU, and products underpinned by nanotechnology are estimated to be worth €2 trillion ([89], p. 93).

The funds allocated in the EU to the assessment of the environmental, health and occupational risks of nanomaterials are low compared to overall investment in nanotechnology R&D. For example, the EU Sixth Framework Programme for R&D (2002–2006), or FP6, devoted 2% (€28 million) of its total expenditure (€1.4 billion) on nanotechnology R&D to risk assessment research ([3], p. 7, [45], p. 3), and FP7 (2007–2013) 2.9% (€102 million) until 2011 ([96], pp. 5, 19).

Namely, in the size range from approximately 1 to 100 nm, according to the definition of the International Organization for Standardization (ISO): https://www.iso.org/obp/ui/#iso:std:iso:19430:ed-1:v1:en:term:3.1. Accessed 21 March 2017.

Due to their shape similarities (long and needle-like), carbon nanotubes have been seen to have asbestos-like impacts on mice [128].

The abovementioned categories of nanomaterials represent classes, and therefore, toxic capacity will be different among single nanomaterials, with relevant variations in their physicochemical properties ([9], p. 335).

The OECD’s Working Party on Manufactured Nanomaterials (WPMN) launched in 2007 a Sponsorship Programme for the Testing of Manufactured Nanomaterials. The goal of this program is to verify the testing methods used on manufactured nanomaterials: http://www.oecd.org/chemicalsafety/nanosafety. Accessed 17 March 2017.

“The Nanodatabase”, developed by the DTU Environment, Danish Ecological Council and Danish Consumer Council. On the database website, the reporting process is described as follows: "Help us improve and expand The Nanodatabase (nano.taenk) by telling us about products that claim to be 'nano' or you think may contain nano materials. Do like this: Search shop shelves and find products, where the word 'Nano' appears on the packaging or on the product itself. (...) After we have received your report, we will contact DTU Environment, who will examine the reported product and in turn authorize its publication in the database". See http://nanodb.dk/en. Accessed 2 March 2017.

In fact, what seems to be at stake is rather more than just developing a new set of rules. Societal regulations are often outpaced by extremely fast, market-oriented mass development and the application of emerging technologies such as nanotechnology, which would arguably demand a new regulatory paradigm—or “predisposition” [144]—based on principles such as flexibility, adaptation and participation [107].

And even where production levels reach the threshold, “the usually low concentration of nanoparticles in the final article is likely to exclude many nanoengineered articles from the REACH legislation, since no registration is required when the concentration of a substance is lower than 0.1% w/w [weight by weight]” ([104], p. 212).

The EC has envisioned amendments to several of the technical provisions in the REACH Annexes ([63, 87], pp. 302–303), expected to be published in May 2017 [38].

This demand needs to be understood in the context of the “functional barrier,” meaning, in the field of intelligent packaging systems, “a barrier within food contact materials or articles preventing the migration of substances from behind the barrier into the food” ([51], p. 4). Behind the functional barrier, substances that are not included in the “Community list” of authorized substances can be used (under certain conditions) ([51], p. 6). Nanoparticles, however, are considered a special technology requiring specific treatment, and they “should not be covered by the functional barrier concept” ([51], p. 4).

The EC is the executive branch of the EU. The European Council confers to the Commission, under certain conditions, or procedures, “powers for the implementation of the rules which the Council lays down” ([24], p. 23).

Ingredients with nanomaterials “shall be followed by the word ‘nano’ in brackets” ([73], p. 73).

Moreover, under this regulation, the EC was required to compile a catalog, by January 2014, of all nanomaterials used in cosmetic products placed on the market, indicating the cosmetic product categories and reasonably foreseeable exposure conditions ([73], p. 71). An annual status report was also to be sent to the EP and European Council on developments in the use of nanomaterials in cosmetic products within the Community, and on issues such as the progress made in developing nanospecific assessment methods and safety assessment guidelines ([73], p. 71).

It should be noted that difficulties relating to the definition of “nanomaterial” transcend the issue of inconsistent formulation. On the one hand, at the moment, there is a lack of one single measurement method to detect and characterize nanomaterials according to defined characteristics, and the task becomes even more complicated when we take into account that the properties of nanomaterials are susceptible to change in their life cycle ([6], p. 411). On the other hand, the limits set by the definition(s) are constitutively (or necessarily) conventional, meaning that materials that do not fall within such limits (i.e., that are not classified as nanomaterials because of their size of percentual presence) may display nanorelated risks in certain contexts of use or in relation to certain properties ([11], p. 122).

Regulatory measures constraining the commercialization and use of GMOs taken in this period, such as the EU moratorium and other safety bans enforced individually by some member states, also seriously affected international trade relations. The importation of GM products to the EU from major producer and exporting countries such as the USA, Canada and Argentina was blocked. In response, the above countries filed a World Trade Organization (WTO) case against the EU, claiming that regulatory measures in Europe were scientifically unjustified and violated compulsory trade agreements. The WTO ruled against the EU, based on legal criteria established by its Appellate Body in other, past disputes, where more precautionary regulations and considerations were approached as illegitimate [156, 157].

In relation to this cautious perspective on the uncertain risks of agri-food biotechnology, Directive 2001/18/EC—unlike previous Directive 90/220/EEC—limited the validity of GMO authorizations to a 10-year period ([70], p. 10). Authorization renewal was granted after a new application detailing the behavior of the GMO during the previous 10-year period had been approved ([70], p. 11).

The public backlash against agri-food biotechnology was not only motivated by safety concerns. Regulatory reforms included rules for the mandatory labeling of products containing GMOs--as already claimed--, mandatory information to the public prior to the commercialization of GMOs, the introduction of ethical advice as an additional criterion for decision-making, and the socio-economic assessment of approved GMOs [70].

For example, Günter Verheugen, former EC Vice President for Enterprise and Industry (2004–2009), stated that “The debate must (…) remain science-based, and we must take a balanced view on matters of concern, such as GMOs, and avoid taking extreme positions” [150].

This is even true of scientific safety assessments. The vulnerability of knowledge to the influence of “subjective,” or ideological, considerations should be approached as characteristic rather than accidental. As the consequences of mistakes in the evaluation of safety hypotheses and models, to a large extent proposed on a relative lack of evidence, are non-epistemological—i.e., they are environmental and sanitary, as well as economic—science-related decisions based on ambiguous and insufficient evidence are said to be necessarily taken under the influence of social criteria ([32], pp. 87–114, [105], pp. 397–403).

The European Food Safety Agency (EFSA) reached the same conclusion [65].

It was estimated that the hazard testing of the nanomaterials available at the time (i.e., 2009), in itself, could take between 3 and 5 decades and would require an investment greater than $1 billion [18].

Synergies between nanomaterials also occur. The agglomeration of nanomaterials may change their properties, which would affect “their behavior in the indoor and outdoor environments as well as their potential exposure and entry into the human body” ([131], p. 7).

The Lisbon Strategy, established in 2000, aimed to make the EU “the most competitive and dynamic knowledge-based economy in the world” by 2010 ([64], p. 12).

NRC experts also make it very clear when stating that “The involvement of decision-makers, technical specialists, and other stakeholders in all phases of the processes leading to decisions should in no way compromise the technical assessment of risk, which is carried out under its own standards and guidelines” ([115], p. 11).

Aarts HJM, van Rie J-PPF, Kok EJ (2002) Traceability of genetically modified organisms. Expert Rev Mol Diagn 2(1):69–76. doi:10.1586/14737159.2.1.69 CrossRef

Abels G (2005) The long and winding road from Asilomar to Brussels: science, politics and the public in biotechnology regulation. Sci Cult 14(4):339–353. doi:10.1080/09505430500369087 CrossRef

Aguar P, Murcia Nicolás JJ (comps) (2008) EU nanotechnology R&D in the field of health and environmental impact of nanoparticles (version: 28 January 08), European Commission, Research DG, Brussels

Amenta V, Aschberger K, Arena M, Bouwmeester H, Moniz FP, Brandhoff P, Gottardo S, Marvin HJP, Mech A, Pesudo LQ, Rauscher H, Schoonjans R, Vettori MV, Weigel S, Peters RJ (2015) Regulatory aspects of nanotechnology in the agri/feed/food sector in EU and non-EU countries. Regul Toxicol Pharmacol 73(1):463–476. doi:10.1016/j.yrtph.2015.06.016 CrossRef

Ansell C, Maxwell R, Sicurelli D (2006) Protesting food: NGOs and political mobilization in Europe. In: Ansell C, Vogel D (eds) What’s the beef? The contested governance of European food safety. The MIT Press, Cambridge, pp 97–122

Aschberger K, Christensen FM, Rasmussen K, Jensen KA (2016) Feasibility and challenges of human health risk assessment for engineered nanomaterials. In: Xing B, Vecitis CD, Senesi N (eds) Engineered nanoparticles and the environment: biophysicochemical processes and toxicity. Wiley, Hoboken, pp 409–441CrossRef

Bauer M (ed) (1995) Resistance to new technology: nuclear power, information technology and biotechnology. Cambridge University Press, Cambridge

Beaudrie CEH, Kandlikar M, Gregory R, Long G, Wilson T (2015) Nanomaterial risk screening: a structured approach to aid decision making under uncertainty. Environ Syst Decis 35(1):88–109. doi:10.1007/s10669-014-9529-y CrossRef

Bhattacharya K, Mukherjee SP, Gallud A, Burkert SC, Bistarelli S, Bellucci S, Bottini M, Star A, Fadeel B (2016) Biological interactions of carbon-based nanomaterials: from coronation to degradation. Nanomedicine: NBM 12(2):333–351. doi:10.1016/j.nano.2015.11.011 CrossRef

10.

Biegelbauer P, Borrás S (eds) (2003) Innovation policies in Europe and the US: the new agenda. Ashgate, Aldershot

11.

Bleeker EAJ, de Jong WH, Geertsma RE, Groenewold M, Heugens EHW, Koers-Jacquemijns M, van de Meent D, Popma JR, Rietveld AG, Wijnhoven SWP (2013) Considerations on the EU definition of a nanomaterial: science to support policy making. Regul Toxicol Pharmacol 65(1):119–125. doi:10.1016/j.yrtph.2012.11.007 CrossRef

12.

Blok V, Lemmens P (2015) The emerging concept of responsible innovation. Three reasons why it is questionable and calls for a radical transformation of the concept of innovation. In: Koops B-J, Oosterlaken I, Romijn H, Swierstra T, van den Hoven J (eds) Responsible innovation 2: concepts, approaches, and applications. Springer, Cham, pp 19–35

13.

Bomberg E (1998) Green parties and politics in the European Union. Routledge, London

14.

Bowman DM, van Calster G, Friedrichs S (2010) Nanomaterials and regulation of cosmetics (correspondence). Nat Nanotechnol 5(2):92. doi:10.1038/nnano.2010.12 CrossRef

15.

Busquin P (2004) Foreword. In: European Commission. Towards a European strategy for nanotechnology. Office for Official Publications of the European Communities, Luxembourg, p 1

16.

Card JW, Zeldin DC, Bonner JC, Nestmann ER (2008) Pulmonary applications and toxicity of engineered nanoparticles. Am J Physiol Lung Cell Mol Physiol 295(3):L400–L411. doi:10.1152/ajplung.00041.2008 CrossRef

17.

Center for International Environmental Law (2014) Nanomaterials definition fact sheet (November 2014). http://www.ciel.org/wp-content/uploads/2015/07/Nano_definition_Nov2014.pdf. Accessed 11 Mar 2017

18.

Choi J-Y, Ramachandran G, Kandlikar M (2009) The impact of toxicity testing costs on nanomaterial regulation. Environ Sci Technol 43(9):3030–3034. doi:10.1021/es802388s CrossRef

19.

Committee on the Environment, Public Health and Food Safety - European Parliament (2007) Report on the proposal for a regulation of the European Parliament and of the Council on food additives (COM(2006)0428 – C6–0260/2006–2006/0145(COD)). FINAL A6–0154/2007, 20.4.2007. Rapporteur: Åsa Westlund

20.

Committee on the Environment, Public Health and Food Safety - European Parliament (2008a) Recommendation for second reading on the Council common position for adopting a regulation on the European Parliament and of the Council on food additives (16675/2/2007 – C6–0141/2008–2006/01/0145(COD)). A6–0180/2008, 13.5.2008. Rapporteur: Åsa Westlund

21.

Committee on the Environment, Public Health and Food Safety - European Parliament (2008b) Report on the proposal for a regulation of the European Parliament and of the Council on cosmetic products (recast) (COM (2008)0049 – C6–0053/2008–2008/0035 (COD)). A6–0484/2008, 8.12.2008. Rapporteur: Dagmar Roth-Behrendt

22.

Committee on the Environment, Public Health and Food Safety - European Parliament (2009) Report on regulatory aspects of nanomaterials (2008/2208 (INI)). A6–0255/2009, 7.4.2009. Rapporteur: Carl Schlyter

23.

Council of the European Communities (1990) Council Directive of 23 April 1990 on the deliberate release into the environment of genetically modified organisms (90/220/EEC). Off J Eur Communities L 117(8.5.90):15–27

24.

Council of the European Union (1999) Council Decision of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (1999/468/EC). Off J Eur Communities L 184/23(17.7.1999):23–26

25.

Council of the European Union (2008) Common position adopted by the Council with a view to the adoption of a Regulation of the European Parliament and of the Council on food additives. Brussels, 29 February 2008. Interinstitutional File: 2006/0145 (COD). 16675/07 ADD 1

26.

Council of the European Union (2010) Council position at first reading with a view to adopting a regulation of the European Parliament and of the Council on novel foods, amending regulation (EC) No 1331/2008 and repealing regulation (EC) No 258/97 and Commission Regulation (EC) No 1852/2001. Brussels, 2 March 2010. Interinstitutional file: 2008/0002 (COD), 11261/09 ADD1 REV 1

27.

Council of the European Union (2014) Council Directive 2014/87/Euratom of 8 July 2014 amending Directive 2009/71/Euratom establishing a Community framework for the nuclear safety of nuclear installations. Off J Eur Union L 219(25.7.2014):42–52

28.

Cranor CF (2017) Tragic failures: how and why we are harmed by toxic chemicals. Oxford University Press, New YorkCrossRef

29.

David K, Thompson PB (eds) (2008) What can nanotechnology learn from biotechnology? Social and ethical lessons for nanoscience from the debate over agrifood biotechnology and GMOs. Academic Press, Amsterdam

30.

Dąbrowska P (2007) Civil society involvement in the EU regulations on GMOs: from the design of a participatory garden to growing trees of European public debate. J Civil Soc 3(3):287–304. doi:10.1080/17448680701775788 CrossRef

31.

Dickson D (1984) The new politics of science. Pantheon Books, New York

32.

Douglas HE (2009) Science, policy, and the value-free ideal. University of Pittsburgh Press, PittsburghCrossRef

33.

Douglas M, Wildavsky A (1982) Risk and culture. An essay on the selection of technological and environmental dangers. University of California Press, Berkeley

34.

Dryzek JS (2000) Deliberative democracy and beyond: liberals, critics, contestations. Oxford University Press, Oxford

35.

Echeverría J (2003) La revolución tecnocientífica. Fondo de Cultura Económica, Madrid

36.

ETC Group (2002) No small matter! Nanotech particles penetrate living cells and accumulate in animal organs. ETC Communiqué 76 (May/June 2002)

37.

ECHA, European Chemicals Agency (2015) Update of the workplan on nanomaterials. 39^th Meeting of the management Board 24–25 September 2015 (MB/41/2015). ECHA, Luxembourg

38.

ECHA (2016) Summary of status of ECHA guidance updates on the REACH regulation relevant to the 31 May 2018 registration deadline not finalized before 31 May 2016—this update as at 22/09/2016. European Union, Helsinki

39.

EC (2000) Communication from the Commission on the precautionary principle. COM(2000) 1 (02.02.2000), Brussels

40.

EC (2001) European governance: a white paper. COM(2001) 428 final (25.7.2001), Brussels

41.

EC (2002) Science and society action plan. Office for Official Publications of the European Communities, Luxembourg

42.

EC (2004) Towards a European strategy for nanotechnology. Office for Official Publications of the European Communities, Luxembourg

43.

EC (2006a) Putting knowledge into practice: a broad-based innovation strategy for the EU. COM(2006) 502 final (13.9.2006), Brussels

44.

EC (2006b) Proposal for a Regulation of the European Parliament and of the Council on food additives. COM(2006) 428 final, 2006/0145 (COD) [28.7.2006], Brussels

45.

EC (2007) Nanosciences and nanotechnologies: an action plan for Europe 2005–2009. First Implementation Report 2005–2007. COM(2007) 505 final (6.9.2007), Brussels

46.

EC (2008a) Regulatory aspects of nanomaterials. COM(2008) 366 final (17.6.2008), Brussels

47.

EC (2008b) Proposal for a Regulation of the European Parliament and of the Council on cosmetic products. COM(2008)49 final/2, 2008/0035 (COD) [14.4.2008], Brussels

48.

EC (2008c) Proposal for a Regulation of the European Parliament and of the Council on novel foods and amending Regulation (EC) No XXX/XXXX [common procedure]. COM (2007) 872 final, 2008/0002 (COD) [14.1.2008], Brussels

49.

EC (2008d) Commission Recommendation of 07/02/2008 on a code of conduct for responsible nanosciences and nanotechnologies research. C(2008) 424 final (07/02/2008), Brussels

50.

EC (2009a) Preparing for our future: developing a common strategy for key enabling technologies in the EU. COM(2009) 512 final (30.09.2009), Brussels

51.

EC (2009b) Commission Regulation (EC) no 450/2009 of 29 May 2009 on active and intelligent materials and articles intended to come into contact with food. Off J Eur Union L 135/3(30.5.2009):3–11

52.

EC (2010) Opinion of the Commission pursuant to Article 294, paragraph 7, point (c) of the Treaty on the Functioning of the European Union, on the European Parliament’s amendments to the Council’s position regarding the proposal for a Regulation of the European Parliament and of the Council on novel foods, amending Regulation (EC) N° 1331/2008 and repealing Regulation (EC) N° 258/97 and Commission Regulation (EC) N° 1852/2001. COM(2010) 570 final, 2008/0002 (COD) [11.10.2010], Brussels

53.

EC (2011a) Regulation (EU) no 10/2011 of 14 January 2011 on plastic materials and articles intended to come into contact with food. Off J Eur Union L 12/1:1–89

54.

EC (2011b) Commission Recommendation of 18 October 2011 on the definition of nanomaterial (2011/696/EU). Off J Eur Union L 275(20.10.2011):38–40

55.

EC (2012a) A European strategy for key enabling technologies—a bridge to growth and jobs. COM(2012) 341 final (26.6.2012), Brussels

56.

EC (2012b) Second regulatory review on nanomaterials. COM(2012) 572 final, Brussels

57.

EC (2013a) Innovation Union: a pocket guide on a Europe 2020 initiative. Publications Office of the European Union, Luxembourg

58.

EC (2013b) Horizon 2020. Work programme 2014–2015: 16. Science with and for society. C(2013)8631 of 10 December 2013, Brussels

59.

EC (2014) Guidance on the protection of the health and safety of workers from the potential risks related to nanomaterials at work. Guidance for employers and health and safety practitioners, Brussels

60.

EC (2015a) Work programme 2014–2015: 5ii. Nanotechnologies, advanced materials, biotechnology and advanced manufacturing and processing (Revised). C(2015)2453 of 17 April 2015, Brussels

61.

EC (2015b) Nanotechnologies (Horizon 2020). http://ec.europa.eu/programmes/horizon2020/en/h2020-section/nanotechnologies. Accessed 23 Oct 2015

62.

EC (2016a) Work programme 2016–2017: 5ii. Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing and Processing. C(2016) 4614 of 25 July 2016, Brussels

63.

EC (2016b) Possible amendments of Annexes to REACH for registration of nanomaterials (Inception Impact Assessment), Brussels

64.

European Council (2000) European Council, 23 and 24 March 2000, Lisbon: conclusions of the Presidency. Bulletin of the European Parliament (27.03.2000), 01/S-2000, PE 289.667, pp 9–29

65.

EFSA (2009) The potential risks arising from nanoscience and nanotechnologies on food and feed safety. Scientific opinion of the scientific committee (question no EFSA-Q-2007-124a). Adopted on 10 February 2009. The EFSA Journal 958:1–39

66.

European Parliament (2009a) European Parliament resolution of 24 April 2009 on regulatory aspects of nanomaterials (2008/2208(INI)). Nanomaterials, P6_TA(2009)0328. Off J Eur Union C 184 E/82(8.7.2010):82–89

67.

European Parliament (2009b) European Parliament legislative resolution of 24 March on the proposal for a regulation of the European Parliament and of the Council on cosmetic products (recast) (COM(2008)0049 – C6-0053/2008 – 2008/0035(COD)). Cosmetic products (recast) ***I, P6_TA(2009)0158. Off J Eur Union C 117 E/223(6.5.2010):223–224

68.

European Parliament (2009c) European Parliament legislative resolution of 25 March 2009 on the proposal for a regulation of the European Parliament and of the Council on novel foods and amending Regulation (EC) no XXX/XXXX [common procedure] (COM(2007)0872 – C6-0027/2008 – 008/0002(COD)). Novel foods ***I, P6_TA(2009)0171. Off J Eur Union C 117 E/236(6.5.2010):236–254

69.

European Parliament (2014) Novel foods: MEPs call for moratorium on nano-foods and labeling of cloned meat. Press Release, 25–11-2014. http://www.europarl.europa.eu/news/en/news-room/20141125IPR80424/novel-foods-meps-call-for-moratorium-on-nano-foods-and-labelling-of-cloned-meat. Accessed 26 Oct 2016

70.

European Parliament and Council of the European Union (2001) Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Off J Eur Communities L 106/1(17.4.2001):1–38

71.

European Parliament and Council of the European Union (2003) Regulation (EC) no 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified food and feed. Off J Eur Union L 268(18.10.2003):1–23

72.

European Parliament and Council of the European Union (2008) Regulation (EC) no 1333/2008 of the European Parliament and of the Council of 16 December 2008 on food additives. Off J Eur Union L 354/16(31.12.2008):16–33

73.

European Parliament and Council of the European Union (2009) Regulation (EC) no 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products (recast). Off J Eur Union L 342/59(22.12.2009):59–209

74.

European Parliament and Council of the European Union (2011) Regulation (EU) no 1169/2011 on the provision of food information to consumers, amending Regulations (EC) no 1924/2006 and (EC) no 1925/2006 of the European Parliament and of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC and Commission Regulation (EC) no 608/2004. Off J Eur Union L 304/18(22.11.2011):18–63

75.

European Parliament and Council of the European Union (2012) Regulation (EU) no 528/2012 of 22 May 2012 concerning the making available on the market and use of biocidal products. Off J Eur Union L 167/1:1–123

76.

European Parliament and Council of the European Union (2013) Regulation (EU) no 1291/2013 of the European Parliament and of the Council of 11 December 2013 establishing Horizon 2020—the Framework Programme for Research and Innovation (2014–2020) and repealing Decision no 1982/2006/EC. Off J Eur Union L 347(20.12.2013):104–173

77.

European Parliament and Council of the European Union (2015a) Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods, amending Regulation (EU) no 1169/2011 of the European Parliament and of the Council and repealing Regulation (EC) no 258/97 of the European Parliament and of the Council and Commission Regulation (EC) no 1852/2001. Off J Eur Union L 327(11.12.2015):1–21

78.

European Parliament and Council of the European Union (2015b) Directive (EU) 2015/412 of the European Parliament and of the Council of 11 March 2015 amending Directive 2001/18/EC as regards the possibility for the member states to restrict or prohibit the cultivation of genetically modified organisms (GMOs) in their territory. Off J Eur Union L 68(13.3.2015):1–8

79.

Felt U, Wynne B et al (2007) Science and governance: taking European knowledge society seriously (EUR 22700). European Commission, Brussels

80.

Ferretti MP (2007) Why public participation in risk regulation? The case of authorizing GMO products in the European Union. Sci Cult 16(4):377–395. doi:10.1080/09505430701706723 CrossRef

81.

Garkov V, Bontoux L, Martin P (2010) Into the unknown. Public Service Review: European Union 19:417–420

82.

Gaskell G (2008) Lessons from the bio-decade: a social scientific perspective. In: David K, Thompson PB (eds) What can nanotechnology learn from biotechnology? Social and ethical lessons for nanoscience from the debate over agrifood biotechnology and GMOs. Academic Press, Amsterdam, pp 237–259

83.

Geoghegan-Quinn M (2010) Introduction. In: European Commission. A decade of EU-funded GMO research (2001–2010) [EUR 24473], Publications Office of the European Union, Luxembourg, pp 7–8

84.

Greenpeace (2015) Guía roja y verde de alimentos transgénicos (5^th edition, 24 June 2015). Greenpeace España, Madrid

85.

Greiving S (rapporteur) (2009) Goverscience seminar on inclusive risk governance (European Commission, EUR 23910), Office for Official Publications of the European Communities, Luxembourg

86.

Hajer MA (1995) The politics of environmental discourse. Ecological modernization and the policy process. Clarendon Press, Oxford

87.

Hansen SF, Baun A (2015) DPSIR and stakeholder analysis of the use of nanosilver. NanoEthics 9(3):297–319. doi:10.1007/s11569-015-0245-y CrossRef

88.

Healy S (2003) Public participation as the performance of nature. In: Szerszynski B, Heim W, Waterton C (eds) Nature performed: environment, culture and performance. Blackwell Pub./The Sociological Review, Oxford, pp 94–108

89.

High-Level Expert Group on Key Enabling Technologies (2015) KETs: time to act (final report, June 2015). European Commission, Brussels

90.

Hristozov D, MacCalman L, Jensen KA, Stone V, Scott-Fordsmand J, Nowack B, Fernandes T, Marcomini A (2014) Risk assessment of engineered nanomaterials: state of the art and roadmap for future research. In: Monteiro-Riviere NA, Tran CL (eds) Nanotoxicology: progress toward nanomedicine, 2nd edn. CRC Press, Boca Raton, pp 459–478CrossRef

91.

Hull M, Bowman D (eds) (2014) Nanotechnology environmental health and safety: risks, regulation, and management, 2nd edn. William Andrew/Elsevier, Oxford

92.

Jahnel J (2015) Addressing the challenges to the risk assessment of nanomaterials. In: Dolez PI (ed) Nanoengineering: global approaches to health and safety issues. Elsevier, Amsterdam, pp 485–521CrossRef

93.

Jamier V, Gispert I, Puntes V (2013) The social context of nanotechnology and regulating its uncertainty: a nanotechnologist approach. J Phys Conf Ser 429(1):012059. doi:10.1088/1742-6596/429/1/012059 CrossRef

94.

Justo-Hanani R, Dayan T (2015) European risk governance of nanotechnology: explaining the emerging regulatory policy. Res Policy 44(8):1527–1536. doi:10.1016/j.respol.2015.05.001 CrossRef

95.

Kandlikar M, Ramachandran G, Maynard A, Murdock B, Toscano WA (2007) Health risk assessment for nanoparticles: a case for using expert judgment. J Nanopart Res 9(1):137–156. doi:10.1007/978-1-4020-5859-2_14 CrossRef

96.

Katalagarianakis G (2011) Overview of the EC EHS research plans and perspective. FP7 and future research needs—most recent calls for proposals and those anticipated. European Commission, Research & Innovation (7^th Framework Programme), 31/03/2011. http://www.nano.gov/sites/default/files/pub_resource/katalagarianakis_march_10.pdf. Accessed 25 Oct 2016

97.

Kershen DL (2014) European decisions about the “whack-a-mole” game. GM Crops 5(1):4–7. doi:10.4161/gmcr.27777 CrossRef

98.

Kimbrell GA (2007) The potential environmental hazards of nanotechnology and the applicability of existing law. In: Cameron NM d S, Mitchell ME (eds) Nanoscale: issues and perspectives for the nano century. Wiley, Hoboken, pp 211–238CrossRef

99.

Kimbrell GA (2009) Governance of nanotechnology and nanomaterials: principles, regulation, and renegotiating the social contract. J Law Med Ethics 37(4):706–723. doi:10.1111/j.1748-720X.2009.00442.x CrossRef

100.

Levidow L, Bijman J (2002) Farm inputs under pressure from the European food industry. Food Policy 27(1):31–45. doi:10.1016/S0306-9192(01)00025-2 CrossRef

101.

Levidow L, Marris C (2001) Science and governance in Europe: lessons from the case of agricultural biotechnology. Sci Public Pol 28(5):345–360. doi:10.3152/147154301781781345 CrossRef

102.

Levidow L, Carr S, Wield D (2005) European Union regulation of agri-biotechnology: precautionary links between science, expertise and policy. Sci Public Pol 32(4):261–276. doi:10.3152/147154305781779452 CrossRef

103.

Levidow L, Murphy J, Carr S (2007) Recasting “substantial equivalence”. Transatlantic governance of GM food. Sci Technol Hum Val 32(1):26–64. doi:10.1177/0162243906293885 CrossRef

104.

Linkov I, Satterstrom FK, Monica JC Jr, Hansen SF, Davis TA (2009) Nano risk governance: current developments and future perspectives. Nanotechnol Law Bus 6(2):203–220

105.

Longino HE (1989) Biological effects of low level radiation: values, dose-response models, risk estimates. Synthese 81(3):391–404. doi:10.1007/BF00869323 CrossRef

106.

Ludlow K (2008) Nanoregulation—filtering out the small stuff. NanoEthics 2(2):183–191. doi:10.1007/s11569-008-0037-8 CrossRef

107.

Marchant GE (2011) The growing gap between emerging technologies and the law. In: Marchant GE, Allenby BR, Herkert JR (eds) The growing gap between emerging technologies and legal-ethical oversight. Springer, Dordrecht, pp 19–33CrossRef

108.

Marklund G, Vonortas NS, Wessner CW (eds) (2009) The innovation imperative: national innovation strategies in the global economy. Edward Elgar, Cheltenham

109.

Marris C, Wynne B, Simmons P, Weldon S (2001) Public perceptions of agricultural biotechnologies in Europe. Final report of the PABE research project (FAIR CT98–3844 [DG12 - SSMI]). PABE, Brussels

110.

Mattsson M-O, Simkó M (2017) The changing face of nanomaterials: risk assessment challenges along the value chain. Regul Toxicol Pharmacol 84:105–115CrossRef

111.

Maynard AD, Aitken RJ, Butz T, Colvin V, Donaldson K, Oberdörster G, Philbert MA, Ryan J, Seaton A, Stone V, Tinkle SS, Tran L, Walker NJ, Warheit DB (2006) Safe handling of nanotechnology. Nature 446:267–269. doi:10.1038/444267a CrossRef

112.

Maynard A, Rejeski D (2009) Too small to overlook. Nature 460:174. doi:10.1038/460174a CrossRef

113.

Meldolesi A (2002) Political will to lift the GMO moratorium emerging in Europe. Nat Biotechnol 20:758–759. doi:10.1038/nbt0802-758 CrossRef

114.

Miller G, Wickson F (2015) Risk analysis of nanomaterials: exposing nanotechnology’s naked emperor. Rev Policy Res 32(4):485–512. doi:10.1111/ropr.12129 CrossRef

115.

NRC-Committee on Improving Risk Analysis Approaches Used by the U.S. EPA, Board on Environmental Studies and Toxicology, Division on Earth and Life Studies (2009) Science and decisions: advancing risk assessment. The National Academies Press, Washington, DC

116.

Nordmann A (2005) Noumenal technology: reflections on the incredible tininess of nano. Techné 8(3):3–23

117.

Oberdörster G (2010) Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. J Intern Med 267(1):89–105. doi:10.1111/j.1365-2796.2009.02187.x CrossRef

118.

Oberdörster G, Maynard A, Donaldson K, Castranova V, Fitzpatrick J, Ausman K, Carter J, Karn B, Kreyling W, Lai D, Olin S, Monteiro-Riviere N, Warheit D, Yang H (2005) Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy. Part Fibre Toxicol 2(8):1–35. doi:10.1186/1743-8977-2-8

119.

OECD (2012a) Important issues on risk assessment of manufactured nanomaterials. Series on the safety of manufactured nanomaterials, No. 33 (ENV/JM/MONO(2012)8), OECD, Paris

120.

OECD (2012b) Six years of OECD work on the safety of manufactured nanomaterials: achievements and future opportunities, OECD, Paris

121.

OECD (2013) Data brief—key biotechnology & nanotechnology indicators: a comparison (November 2013), OECD, Paris

122.

OECD (2014) Report of the questionnaire on regulatory regimes for manufactured nanomaterials 2010–2011. Series on the safety of manufactures nanomaterials, No. 42 (ENV/JM/MONO(2014)28), OECD, Paris

123.

OECD (2015a) Science, technology and industry scoreboard 2015: innovation for growth and society, OECD, Paris

124.

OECD (2015b) The innovation imperative: contribution to productivity, growth and well-being, OECD, Paris

125.

Palmberg C, Dernis H, Miguet C (2009) Nanotechnology: an overview based on indicators and statistics. STI Working paper 2009/7, OECD, Paris

126.

Pellizzoni L (2001) Democracy and the governance of uncertainty: the case of agricultural gene technologies. J Hazard Mater 86(1–3):205–222CrossRef

127.

Pellizzoni L (2015) Ontological politics in a disposable world: the new mastery of knowledge. Ashgate, Farnham

128.

Poland CA, Duffin R, Kinloch I, Maynard A, Wallace WAH, Seaton A, Stone V, Brown S, MacNee W, Donaldson K (2008) Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nat Nanotechnol 3:423–428. doi:10.1038/nnano.2008.111 CrossRef

129.

Rauscher H, Rasmussen K, Sokull-Klüttgen B (2017) Regulatory aspects of nanomaterials in the EU. Chem Ing Tech 89(3):224–231. doi:10.1002/cite.201600076 CrossRef

130.

Ravetz J (2003) A paradoxical future for safety in the global knowledge economy. Futures 35(8):811–826. doi:10.1016/S0016-3287(03)00037-5 CrossRef

131.

Ray PC, Yu H, Fu PP (2009) Toxicity and environmental risks of nanomaterials: challenges and future needs. J Environ Sci Health C 27(1):1–35. doi:10.1080/10590500802708267 CrossRef

132.

Ricaud M, Witschger O (2012) Nanomaterials: definitions, toxicological risk, characterisation of occupational exposure and prevention measures (ED 6050). Institut National de Recherche et de Sécurité (INRS), Paris

133.

Roco MC (2016) National nanotechnology investment in the FY 2017 budget. In: American Association for the Advancement of Science (AAAS) and Intersociety Working Group. Science & Technology in Congress FY 2017. AAAS, Washington, DC, pp 78–84

134.

Rodríguez H (2016) From objective to constituted risk: an alternative approach to safety in strategic technological innovation in the European Union. J Risk Res 19(1):42–55. doi:10.1080/13669877.2014.940596 CrossRef

135.

Rodríguez H, Fisher E, Schuurbiers D (2013) Integrating science and society in European Framework Programmes: trends in project-level solicitations. Res Policy 42(5):1126–1137. doi:10.1016/j.respol.2013.02.006 CrossRef

136.

Roszak T (1969) The making of a counter culture: reflections on the technocratic society and its youthful opposition. Doubleday, Garden City

137.

SCENIHR (2006) Modified opinion (after public consultation) on: the appropriateness of existing methodologies to assess the potential risks associated with engineered and adventitious products of nanotechnologies. European Commission, Health & Consumer Protection Directorate-General, Brussels

138.

SCENIHR (2007) Opinion on the appropriateness of the risk assessment methodology in accordance with the technical guidance documents for new and existing substances for assessing the risks of nanomaterials. European Commission, Directorate-General for Health & Consumer Protection, Brussels

139.

SCENIHR (2009) Risk assessment of products of nanotechnologies. European Commission, Directorate-General for Health & Consumers, Brussels

140.

SCENIHR (2010) Scientific basis for the definition of the term “nanomaterial”. European Commission, Directorate-General for Health & Consumers, Brussels

141.

SCHER, SCENIHR, SCCS (2013) Making risk assessment more relevant for risk management. European Commission, Directorate-General for Health & Consumers, Brussels

142.

Shrader-Frechette K (2007) Taking action, saving lives: our duties to protect environmental and public health. Oxford University Press, OxfordCrossRef

143.

Sodano V, Gorgitano MT, Quaglietta M, Verneau F (2016) Regulating food nanotechnologies in the European Union: open issues and political challenges. Trends Food Sci Tech 54:216–226. doi:10.1016/j.tifs.2016.05.022 CrossRef

144.

Stokes E (2012) Nanotechnology and the products of inherited regulation. J Law Soc 39(1):93–112. doi:10.1111/j.1467-6478.2012.00572.x CrossRef

145.

Thompson EA, Sayers BC, Glista-Baker EE, Shipkowski KA, Taylor AJ, Bonner JC (2014) Innate immune responses to nanoparticle exposure in the lung. J Environ Immunol Toxicol 1(3):150–156. doi:10.7178/jeit.23

146.

Tokamanis C (2011) Nanotechnology becomes a socio-political project (interview). In: Bonazzi M (ed) Successful European nanotechnology research. Outstanding science and technology to match the needs of future society. Publications Office of the EU, Luxembourg, pp 9–12

147.

Tomellini R (2003) Is nanotechnology dangerous? “We need to know”, says Renzo Tomellini (interview) EurActiv: EU news and policy debates across languages (17 November 2003). http://www.euractiv.com/section/nanotechnology/news/is-nanotechnology-dangerous-we-need-to-know-says-renzo-tomellini/. Accessed 22 March 2017

148.

UNESCO (2016) Nanotechnology is a growing research priority. http://www.unesco.org/new/en/natural-sciences/science-technology/single-view-sc-policy/news/nanotechnology_is_a_growing_research_priority/. Accessed 24 Feb 2017

149.

van Calster G (2009) Simply swallow?—the application of nanotechnologies in European food law. Eur Food and Feed Law Rev 4(3):167–171

150.

Verheugen G (2005) The Commission’s new biotech policy (SPEECH/05/536). Presented at the Biotechnology Policy Day High Level Roundtable. Brussels, 22 September 2005. http://europa.eu/rapid/press-release_SPEECH-05-536_1.htm. Accessed 29 Nov 2014

151.

von Schomberg R (2010) Introduction: understanding public debate on nanotechnologies. Options for framing public policy. In: von Schomberg R, Davies S (eds) Understanding public debate on nanotechnologies. Options for framing public policy (a report from the European Commission services). European Commission, Brussels, pp 5–12

152.

von Schomberg R (2013) A vision of responsible research and innovation. In: Owen R, Bessant J, Heintz M (eds) Responsible innovation: managing the responsible emergence of science and innovation in society. Wiley, Chichester, pp 51–74CrossRef

153.

Walker NJ, Bucher JR (2009) A 21st century paradigm for evaluating the health hazards of nanoscale materials? Toxicol Sci 110(2):251–254. doi:10.1093/toxsci/kfp106 CrossRef

154.

Welsh I, Wynne B (2013) Science, scientism and imaginaries of publics in the UK: passive objects, incipient threats. Sci Cult 22(4):540–566. doi:10.1080/14636778.2013.764072 CrossRef

155.

Wickson F (2009) What you should know about nano (policy brief no. 8, November 2009). The Australian Institute (TAI), Canberra

156.

Winham GR (2009) The GMO panel: applications of WTO law to trade in agricultural biotech products. J Eur Integr 31(3):409–429. doi:10.1080/07036330902782261 CrossRef

157.

Wirth DA (2013) The World Trade Organization dispute over genetically modified organisms: the precautionary principle meets international trade law. Vermont Law Rev 37(4):1153–1188

158.

Wynne B (2010) Strange weather, again: climate science as political art. Theory Cult Soc 27(2–3):289–305. doi:10.1177/0263276410361499 CrossRef

Titel: Nanotechnology and Risk Governance in the European Union: the Constitution of Safety in Highly Promoted and Contested Innovation Areas
verfasst von: Hannot Rodríguez
Publikationsdatum: 05.08.2017
Verlag: Springer Netherlands
Erschienen in: NanoEthics / Ausgabe 1/2018
Print ISSN: 1871-4757
Elektronische ISSN: 1871-4765
DOI: https://doi.org/10.1007/s11569-017-0296-3

Springer Professional

Abstract

Bitte loggen Sie sich ein, um Zugang zu Ihrer Lizenz zu erhalten.

Sie haben noch keine Lizenz? Dann Informieren Sie sich jetzt über unsere Produkte:

Springer Professional "Wirtschaft+Technik"

Springer Professional "Wirtschaft"

Weitere Artikel der Ausgabe 1/2018

Ethics in Technology: a Philosophical Study

How to Address the Policy and Ethical Issues Emerging with New Technology. The Case of Synthetic Biology in a Small Country

Decision Support for International Agreements Regulating Nanomaterials

Governing with Ignorance: Understanding the Australian Food Regulator’s Response to Nano Food

Discussions of Risk and New Approaches to Responsible Research and Innovation

Person Skilled in the Art in Synthetic Biology from Iraqi and Malaysian Perspectives

Premium Partner